EUCTR2008-006156-22-DE进行中（未招募）不适用
A single-blind, multiple dose, placebo-controlled, double dummy study to investigate the pharmacodynamic and pharmacokinetic interaction between aliskiren and furosemide in patients with heart failure.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males or females, aged between 18 and 75 years (inclusive) at screening.
- •2. Female patients of childbearing potential must be using an acceptable form of contraception, Postmenopausal females must have had no regular menstrual bleeding for at least one (1) year prior to screening.
- •Female patients who report surgical sterilization must have had the procedure at least six (6) months prior to screening.
- •3. All patients must be diagnosed at least 3 months prior to screening with either systolic or diastolic heart failure with signs and symptoms of congestive heart failure and NYHA functional class II or III symptoms AND be on stable medication for at least 12 weeks (furosemide only stable for 3 weeks)
- •4. A patient has to fulfill either a), or b) to qualify for participation
- •(a) Patients with a documented left ventricular ejection fraction(LVEF) greater than 20% but lower than 40%
- •(b) Patients with a documented left ventricular ejection fraction (LVEF) greater than 40% AND with a history of NT-pro-BNP > 400 pg/mL (or BNP > 100 pg/mL) within 12 months of screening.
- •5. Patients must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) of maximum 40 kg/m2.
- •6. Patients must be able to communicate well with the investigator, to understand and comply with the requirements of the study, and to understand and sign the written informed consent.
- •For a detailed list of inclusion criteria, please refer to the full protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Treatment with Angiotensin Receptor Blockers (ARBs), aldosterone receptor antagonists and diuretics (other than furosemide) within 3 weeks of first dose and during the study. Beta blockers are permitted providing the dose has been stable for at least 3 weeks before the first dose and remains so throughout the study.
- •2. Hypertrophic cardiomyopathy (HCMP).
- •3. If a subject is currently treated with furosemide, the dose must be stable for at least 3 weeks before the first dose and the dose must not exceed 60 mg daily.
- •4. Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase 2 (COX-2) inhibitors within 72 hours prior to first dose or during the 24 hour in-clinic study periods.
- •5. Treatment with sildenafil (Viagra), vardenafil (Levitra), or tadalafil (Cialis) within 72 hours prior to first dose or during the 24 hour in-clinic study periods.
- •6. Commencing any new medication during the conduct of the study that could affect renal function or serum creatinine.
- •7. Stable heart failure requiring treatment with both an ACE inhibitor and an ARB.
- •8. msSBP =160 mmHg and/or msDBP = 100mmHg and/or secondary forms of hypertension.
- •9. Persistent sitting systolic blood pressure <90 mmHg.
- •10. Signs or symptoms of dehydration (BUN/sCr ratio; orthostatic hypotension) as judged to be clinically significant by the investigator.
- •11. Uncontrolled diabetes based on the investigator’s clinical judgement, and glucose/HbA1c measurements.
- •12. History of angioedema.
- •For a full list of exclusion criteria, please refer to the full protocol.
研究者
相似试验
进行中（未招募）
不适用
A clinical trial on the interaction between aliskiren and furosemide in patients with heart failure.Essential hypertensionMedDRA version: 14.0Level: PTClassification code 10015488Term: Essential hypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2008-006156-22-LTovartis Pharma Services AG28
进行中（未招募）
不适用
Study of efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosisPulmonary sarcoidosisMedDRA version: 17.1Level: PTClassification code 10037430Term: Pulmonary sarcoidosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2013-005333-21-NLovartis Pharma Services AG90
已完成
1 期
An assessment of the safety and pharmacokinetic of ascending doses of sanguinate (Trademark) in healthy volunteersACTRN12612001033831Prolong Pharmaceuticals24
已完成
不适用
Phase 2a study for NASHKCT0008007J2H Biotech16
已完成
1 期
Phase I study to assess the safety and tolerability of inhaled interferon-beta (IFN-beta1a) in controlled asthmatic male and female subjectsAsthmaISRCTN83107787Synairgen Research Limited (UK)40